IRulya Therapeutics (IRLA) Fireside Chat (FKA Orphai) - IRULYA THERAPEUTICS INC

Explicit Guidance:

• No explicit financial guidance provided (revenue, earnings, margins, capex, etc.) due to the company's pre-commercial clinical stage status.
• Cash Runway: Current cash and cash equivalents are expected to fund operations through the end of 2028.
• Clinical Milestone Timelines:
  • BOS (Bronchiolitis Obliterans Syndrome) Phase II: Data readout anticipated in Q1 2027.
  • PHILD (Pulmonary Hypertension associated with Interstitial Lung Disease) Phase IIb: Data readout anticipated in Q1 2029 (transcript stated "2020" contextually implies 2029 based on Phase IIb sequencing).
  • SAPH (Sarcoidosis-associated Pulmonary Hypertension) Phase II: Data readout anticipated in Q4 2030 (transcript stated "2018" contextually implies 2030 based on study initiation timeline).

Business-Segment Outlook:

• Lung Disease Portfolio Strategy: Focus on three specific indications: BOS, PHILD, and SAPH, leveraging a proprietary inhaled rapamycin formulation (LAM-001) to bypass systemic toxicities associated with oral administration.
• Market Sizing Projections:
  • BOS: Expected patient population to grow to approximately 25,000–30,000 patients (US and Europe combined) by the early 2030s, driven by a rising lung transplant volume (projected to reach nearly 4,000 procedures/year in the US, up from ~2,500 six years ago).
  • PHILD: Identified as a larger market compared to BOS; currently multiple players active.
  • SAPH: Estimated 30,000 patients in the US (subset of ~200,000 pulmonary sarcoidosis patients where ~15% develop PH) and comparable numbers in Europe.
• Product Positioning: LAM-001 is positioned for combination therapy; management anticipates it will be compatible with existing background therapies (e.g., pulmonary vasodilators) and potentially Roivant's upcoming Phase III drug, without cannibalizing future value.

Market and Competitive Outlook:

• Competitive Landscape: No approved treatments currently exist for BOS or SAPH-associated PH. For PHILD, the company acknowledges competition from troprosinols and other pipeline agents but differentiates via mechanism of action (mTOR inhibition vs. vasodilation).
• Pricing/Reimbursement: No specific pricing guidance; focus remains on establishing clinical utility in underserved, high-mortality orphan indications.
• Treatment Paradigm Shift: Anticipates a shift toward disease-modifying therapies targeting fibrosis and vascular proliferation rather than just symptom management, specifically in BOS where current care is limited to symptom palliation.

Macro / Industry Outlook:

• Demographic Trends: Growth in lung transplant volumes (driven by expanded use of marginal organs and perfusion devices) is expected to directly expand the addressable patient pool for BOS over the next decade.
• Regulatory Environment: Study designs are structured to satisfy standard regulatory requests for dose analysis (e.g., 100mcg vs. 200mcg) and placebo-controlled arms.
• Clinical Standards: Management notes that current standard of care in PHILD (placebo arms in historical studies) shows a 6.6% to 18.2% increase in Pulmonary Vascular Resistance (PVR) over 24 weeks, providing a baseline for efficacy comparisons.

Strategic Initiatives:

• Phase II BOS Study (Ongoing): Investigator-sponsored trial at UCSF (19 patients); primary focus is on demonstrating a 5% to 10% delta in FEV1 decline reduction between arms to support pivotal study advancement. No expectation of statistical significance or disease reversal, but survival correlation is key (1% FEV1 decline = 3.4% mortality increase).
• Phase IIb PHILD Study: Powered at 80% to detect a 20% difference in PVR (25% standard deviation) with 75 patients. Will include a placebo arm and assess both 100mcg and 200mcg doses in Functional Class 2 and 3 patients.
• Phase II SAPH Study: Expected to initiate "in the very near future" to evaluate impact on granulomas and pulmonary hypertension in sarcoidosis patients.
• Formulation Optimization: Continued focus on dry powder inhaler (DPI) delivery to achieve high lung tissue exposure with only 100mcg dose (1/20th of oral dose), minimizing systemic side effects and cough.

Risks and Headwinds to Outlook:

• Clinical Risk: The BOS study is a small (19-patient) investigator-sponsored trial; while a 5–10% delta is the target for clinical meaningfulness, the sample size limits statistical power.
• Safety Risk: While the inhaled formulation aims to avoid systemic toxicities of oral rapamycin, safety monitoring remains critical, particularly in immunosuppressed transplant patients (BOS population).
• Disease Progression: BOS is described as an "irreversible" fibroproliferative process; management notes that reversing FEV1 decline is a "homerun" rather than the primary expectation, with stabilization being the likely success metric.
• Commercialization Lag: No commercial product exists yet; revenue generation is dependent on successful pivotal trials and subsequent regulatory approval, which could face delays beyond current timelines.

Management Tone on the Future:

• Confidence Level: High confidence in the drug's mechanism and the "dual compartment" targeting of vascular and parenchymal disease in PHILD.
• Cautious Realism: Explicitly manages expectations for the BOS readout, stating no statistical significance is expected and defining "success" as a clinically meaningful survival-correlated delta rather than statistical proof in this small cohort.
• Strategic Patience: Tone suggests a long-term view on portfolio expansion, acknowledging the "dire consequences" of current untreated conditions and positioning the company as a first-mover in multiple orphan indications.

Miscellaneous:

• Company Name Change: Renamed from "Irulia" (implied) to "Irulio" to reflect "Inhaled Rapamycin" and the vision "Unlocking Life-Extending Years of Airflow."
• Stock Symbol/Ticker: Not explicitly mentioned in transcript, but identified as a biotech company presenting at the "Craig Hallam Biotec Catalyst Conference."
• Key Personnel: Bridget Roberts (CEO), Keith Vandrick (COO), Patrick Sarmier (SVP Clinical Research), John Mitello (CFO).